SAN DIEGO, CA--(Marketwire - November 05, 2012) - NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today that due to the continued uncertainty of transportation in New York City, the Company's Investor Event has been moved from Wednesday, November 7, 2012 to Wednesday, November 14, 2012. The event will take place from 9:00 a.m. - 12:00 p.m. ET at the Company's NuVasive East office located in Paramus, New Jersey.
The event will be hosted by Alex Lukianov, Chairman and Chief Executive Officer, and will feature a panel of leading U.S. spine surgeons. As well, Keith Valentine, President and Chief Operating Officer, will provide a product overview, Michael Lambert, Executive Vice President and Chief Financial Officer, will provide a financial update, and Kelli Howell, Vice President of Research, will present a strategic update on NuVasive's clinical efforts.
The agenda will include:
- Executive management's plan to re-establish momentum and address industry challenges
- A review of the company's key growth drivers, future catalysts, and financial projections
- A cadaveric demonstration of the Company's recently approved PCM® Cervical Disc including clinical support references and direct comparisons to competitive devices
- Clinical evidence demonstrating the advantages of XLIF compared to other approaches for spine fusion and to other lateral products
- A discussion about the state of the U.S. Spine Market and an overview of the competitive dynamics by NuVasive sales executives
- An in depth review of the breadth and depth of the Company's product portfolio, including recent product launches at NASS and the game changing product roadmap for the future
- An update on the Company's expansion outside the United States
- Ample time for audience Q&A
Registration and product demonstrations will begin at 8:45 a.m., followed by the formal presentation from 9:30 a.m. to 12:00 p.m.
A live webcast of the meeting will be available online from the investor relations page of the Company's corporate website at www.nuvasive.com. After the live webcast, the presentation will remain available on the website for 30 days.
NuVasive is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $7.9 billion global spine market.
NuVasive's principal product offering is based on its Maximum Access Surgery, or MAS® platform. The MAS platform combines several categories of solutions that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: a proprietary software-driven nerve avoidance system and intra-operative monitoring support; MaXcess®, a unique split-blade retractor system; a wide variety of specialized implants; and several biologic fusion enhancers. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform's lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF®, NuVasive has built an entire spine franchise. With over 75 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness®.
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that insurance payers may refuse to reimburse healthcare providers for the use of NuVasive's products; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.